Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies IV: Magnetic Resonance Imaging01:27

Imaging Studies IV: Magnetic Resonance Imaging

219
Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...
219
Magnetic Resonance Imaging01:24

Magnetic Resonance Imaging

9.0K
Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radioligand Therapy for Prostate Cancer - A Clinical Consultation Guide.

European urology focus·2026
Same author

Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

The Lancet. Oncology·2026
Same author

Avoiding Prostate Biopsy in Early Prostate Cancer Detection: From Liquid Biopsy to PSMA-PET.

European urology focus·2026
Same author

Neoadjuvant Treatment for Penile Cancer: A Systematic Review of Contemporary Evidence.

Cancers·2026
Same author

Granulomatous prostatitis masquerading as suspected prostate cancer in a young patient on immunotherapy for psoriasis.

BMJ case reports·2026
Same author

Utility of PSMA PET/CT for staging of favourable risk intermediate risk prostate cancer.

European journal of nuclear medicine and molecular imaging·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Jan 13, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

1.1K

Using Artificial Intelligence as a Risk Prediction Model in Patients with Equivocal Multiparametric Prostate MRI

Abdullah Al-Khanaty1,2, David Hennes1,3, Arjun Guduguntla2

  • 1Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Cancers
|January 10, 2026
PubMed
Summary
This summary is machine-generated.

Artificial intelligence (AI) can improve the detection of clinically significant prostate cancer (csPCa) in PI-RADS 3 lesions, reducing unnecessary biopsies. AI models show promise in matching or exceeding radiologist performance, aiding in better patient management.

Keywords:
PI-RADS 3artificial intelligencedeep learningmachine learningmultiparametric MRIprostate cancerradiomics

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

22.3K
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

1.1K

Related Experiment Videos

Last Updated: Jan 13, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

1.1K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

22.3K
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

1.1K

Area of Science:

  • Radiology
  • Medical Imaging
  • Artificial Intelligence

Background:

  • PI-RADS 3 lesions on multiparametric MRI (mpMRI) present a diagnostic challenge, with a low detection rate of clinically significant prostate cancer (csPCa).
  • This diagnostic uncertainty leads to both unnecessary biopsies and missed csPCa diagnoses.
  • Artificial intelligence (AI) offers a potential solution for objective and reproducible risk stratification of these indeterminate findings.

Purpose of the Study:

  • To review current evidence on AI applications for risk stratification in PI-RADS 3 lesions.
  • To clarify the role of multicentre initiatives like the PI-CAI study in benchmarking AI against expert radiologists.

Main Methods:

  • A narrative review of PubMed and Embase databases was performed.
  • Studies evaluating AI for csPCa prediction in PI-RADS 3 lesions using biopsy or follow-up as reference standards were included.
  • Emphasis was placed on externally validated AI models.

Main Results:

  • Radiomics and deep learning AI models demonstrate ability to distinguish csPCa from benign tissue in PI-RADS 3 lesions.
  • AI can potentially reduce benign biopsy rates by 30-40% and improve csPCa detection.
  • The PI-CAI study indicates AI systems can match or exceed expert radiologists in csPCa detection across diverse settings.

Conclusions:

  • AI holds significant potential to improve the management of PI-RADS 3 lesions by reducing unnecessary biopsies and enhancing csPCa detection.
  • Further prospective, multicentre validation and integration into clinical workflows are necessary for routine adoption.
  • Harmonised imaging protocols and clear decision support are crucial for successful AI implementation.